Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, randomized, placebo-controlled, ascending dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of HL161BKN following single intravenous and subcutaneous doses in healthy subjects

Trial Profile

A Phase 1, randomized, placebo-controlled, ascending dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of HL161BKN following single intravenous and subcutaneous doses in healthy subjects

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HL 161 (Primary) ; HL 161 (Primary)
  • Indications Autoimmune disorders; Graves ophthalmopathy; Myasthenia gravis
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 09 May 2019 According to a Roivant Sciences media release, the first detailed findings from this study will be presented at the 2019 American Academy of Neurology (AAN) Annual Meeting.
    • 07 Jan 2019 According to a Roivant Sciences media release, updated data form this study will be presented at the J.P. Morgan Healthcare Conference.
    • 10 Jul 2018 According to a Roivant Sciences media release, preliminary clinical data from this study will be presented today at the First Annual Pipeline Day of the Company.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top